Fundraising FoxZentynel Frontier Investments — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Respirarespiratherapeutics.comin𝕏Feb 2022 · $2.8M
Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension.
BiotechDigital HealthHealthtechMedical Devices
John Kollins(Chief Executive Officer)in
Co-investorsCottonwood Technology FundSamsara BioCapital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.